Literature DB >> 8258201

Acute mucocutaneous toxicity following high-dose hydroxyurea.

H Brincker1, B E Christensen.   

Abstract

Three patients with advanced acute myeloid leukemia were treated with oral high-dose hydroxyurea at a dose of 10 g daily for 8-10 days. Severe acute stomatitis developed in all three patients. In addition, two of the patients developed a peculiar acute cutaneous type of toxicity associated with soreness, violet erythema, and edema of the palms and foot soles followed by intense universal hyperpigmentation of the skin. Apparently, the pronounced acute mucocutaneous toxicity was caused by the sustained high daily dose of hydroxyurea, indicating that myelosuppression may not be the dose-limiting toxicity of this drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258201     DOI: 10.1007/bf00685897

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  An overview of the clinical experience with hydroxyurea.

Authors:  R C Donehower
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

2.  A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia.

Authors:  J E Kolitz; S J Kempin; A Schluger; G Y Wong; E Berman; S Jhanwar; Z A Arlin; T Gee; B D Clarkson
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

3.  High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent.

Authors:  W P Vaughan; P J Bierman; E C Reed; L D Glenn; A Kessinger; J O Armitage
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

Review 4.  Mechanism of action of hydroxyurea.

Authors:  J W Yarbro
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

Review 5.  The evolution of hydroxyurea therapy in chronic myelogenous leukemia.

Authors:  B J Kennedy
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

6.  Split-course irradiation compared to split-course irradiation plus hydroxyurea in inoperable bronchogenic carcinoma--a randomized study of 53 patients.

Authors:  R C Landgren; D H Hussey; H T Barkley; M L Samuels
Journal:  Cancer       Date:  1974-11       Impact factor: 6.860

7.  Phase 1 study of high-dose hydroxyurea in lung cancer.

Authors:  D Veale; B M Cantwell; N Kerr; A Upfold; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.

Authors:  J J Lokich; C Moore
Journal:  Ann Intern Med       Date:  1984-12       Impact factor: 25.391

9.  Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia.

Authors:  F M Grund; J O Armitage; P Burns
Journal:  Arch Intern Med       Date:  1977-09

10.  Skin changes secondary to hydroxyurea therapy.

Authors:  B J Kennedy; L R Smith; R W Goltz
Journal:  Arch Dermatol       Date:  1975-02
  10 in total
  3 in total

1.  Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial.

Authors:  Anncarin Svanberg; Gunnar Birgegård; Kerstin Ohrn
Journal:  Support Care Cancer       Date:  2007-03-29       Impact factor: 3.603

2.  Hydroxyurea and colonic ulcers: a case report.

Authors:  Kochawan Boonyawat; Sansanee Wongwaisayawan; Prawat Nitiyanant; Vichai Atichartakarn
Journal:  BMC Gastroenterol       Date:  2014-07-31       Impact factor: 3.067

3.  Laser Photobiomodulation for a Complex Patient with Severe Hydroxyurea-Induced Oral Ulcerations.

Authors:  Marco Cabras; Adriana Cafaro; Alessio Gambino; Roberto Broccoletti; Ercole Romagnoli; Davide Marina; Paolo G Arduino
Journal:  Case Rep Dent       Date:  2016-11-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.